Abstract:The lack of predictive preclinical models is a fundamental barrier to translating knowledge about the molecular pathogenesis of cancer into improved therapies. Insertional mutagenesis (IM) in mice is a robust strategy for generating malignancies that recapitulate the extensive inter- and intra-tumoral genetic heterogeneity found in advanced human cancers. While the central role of "driver" viral insertions in IM models that aberrantly increase the expression of proto-oncogenes or disrupt tumor suppressors has been appreciated for many years, the contributions of cooperating somatic mutations and large chromosomal alterations to tumorigenesis are largely unknown. Integrated genomic studies of T lineage acute lymphoblastic leukemias (T-ALLs) generated by IM in wild-type (WT) and Kras mutant mice reveal frequent point mutations and other recurrent non-insertional genetic alterations that also occur in human T-ALL. These somatic mutations are sensitive and specific markers for defining clonal dynamics and identifying candidate resistance mechanisms in leukemias that relapse after an initial therapeutic response. Primary cancers initiated by IM and resistant clones that emerge during in vivo treatment close key gaps in existing preclinical models, and are robust platforms for investigating the efficacy of new therapies and for elucidating how drug exposure shapes tumor evolution and patterns of resistance. Author summary A lack of predictive cancer models is a major bottleneck for prioritizing new anti-cancer drugs for clinical trials. We comprehensively profiled a panel of primary mouse T lineage leukemias initiated by insertional mutagenesis and found remarkable similarities with human T-ALL in regard to overall mutational burden, the occurrence of specific somatic mutations and large chromosomal alterations, and concordant gene expression signatures. We observed frequent duplication of the Kras oncogene with loss of the normal allele, which has potential therapeutic implications that merit further investigation in human leukemia and in other preclinical models. Mutations identified in mouse leukemias that relapsed after in vivo treatment with signal transduction inhibitors were also observed in relapsed human T-ALL, indicating that this model system can be utilized to investigate strategies for overcoming intrinsic and acquired drug resistance. Finally, preclinical models similar to the one described here that are characterized by a normal endogenous tumor microenvironment and intact immune system will become increasingly important for testing immunotherapy approaches for human cancer.

How Animal Models of Leukaemias Have Already Benefited Patients

Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia.

How patients have benefited from mouse models of acute promyelocytic leukaemia

Mouse models for pre-clinical drug testing in leukemia

New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia

Research advances of the leukemia animal models

Use of rodents as models of human diseases

Modeling leukemia with zebrafish (Danio rerio): Towards precision medicine

Humanized mouse models: A valuable platform for preclinical evaluation of human cancer

Orthotopic and metastatic tumour models in preclinical cancer research

Studying the pathogenesis of BCR–ABL+ leukemia in mice

Animal models for modeling pancreatic cancer and novel drug discovery

Mouse models of CLL: In vivo modeling of disease initiation, progression, and transformation

Modeling the dosage effect of oncogenes in leukemogenesis.

The evolution of preclinical models for myelodysplastic neoplasms

If you give a mouse a mutation: comparing the therapeutic utility of renowned mouse models of human cancers

Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias.

The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies

An overview of chronic myeloid leukemia and its animal models

In Vitro and In Vivo Modeling of Normal and Leukemic Bone Marrow Niches: Cellular Senescence Contribution to Leukemia Induction and Progression

Translation of Data from Animal Models of Cancer to Immunotherapy of Breast Cancer and Chronic Lymphocytic Leukemia